Literature DB >> 9188561

Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission.

P Putkonen1, B Mäkitalo, D Böttiger, G Biberfeld, R Thorstensson.   

Abstract

At present it is not known which form of immunity would be most effective against infection with human immunodeficiency virus (HIV). To evaluate the possible role of cellular immunity, we examined whether four HIV type 2-exposed but seronegative macaques developed cellular immune responses and determined whether these exposed macaques were resistant to mucosal transmission of simian immunodeficiency virus (SIV). Following intrarectal challenge with SIV, 2 monkeys were protected against detectable SIV replication and another showed suppressed viral replication compared to 14 persistently infected controls. The two protected monkeys demonstrated SIV-specific cytotoxic T lymphocytes before as well as after SIV challenge. Here we provide evidence that activation of the cell-mediated arm of the immune system only, without antibody formation, can control SIV replication in macaques. The results imply that vaccines that stimulate a strong and broad cellular immune response could prevent mucosal HIV transmission.

Entities:  

Mesh:

Year:  1997        PMID: 9188561      PMCID: PMC191729          DOI: 10.1128/JVI.71.7.4981-4984.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3'-fluorothymidine.

Authors:  D Böttiger; P Putkonen; B Oberg
Journal:  AIDS Res Hum Retroviruses       Date:  1992-07       Impact factor: 2.205

2.  Anti-cell antibody in macaques.

Authors:  E J Stott
Journal:  Nature       Date:  1991-10-03       Impact factor: 49.962

3.  Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys.

Authors:  S Andersson; B Mäkitalo; R Thorstensson; G Franchini; J Tartaglia; K Limbach; E Paoletti; P Putkonen; G Biberfeld
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

4.  Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys.

Authors:  P Putkonen; R Thorstensson; L Ghavamzadeh; J Albert; K Hild; G Biberfeld; E Norrby
Journal:  Nature       Date:  1991-08-01       Impact factor: 49.962

5.  A strategy for prophylactic vaccination against HIV.

Authors:  J Salk; P A Bretscher; P L Salk; M Clerici; G M Shearer
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

6.  Vaccine protection against HIV-2 infection in cynomolgus monkeys.

Authors:  P Putkonen; R Thorstensson; L Walther; J Albert; L Akerblom; O Granquist; G Wadell; E Norrby; G Biberfeld
Journal:  AIDS Res Hum Retroviruses       Date:  1991-03       Impact factor: 2.205

7.  Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers.

Authors:  R Cheynier; P Langlade-Demoyen; M R Marescot; S Blanche; G Blondin; S Wain-Hobson; C Griscelli; E Vilmer; F Plata
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

8.  HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.

Authors:  S L Rowland-Jones; D F Nixon; M C Aldhous; F Gotch; K Ariyoshi; N Hallam; J S Kroll; K Froebel; A McMichael
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

9.  Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells.

Authors:  R C Hom; R W Finberg; S Mullaney; R M Ruprecht
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

View more
  14 in total

Review 1.  Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge.

Authors:  R K S Ahmed; B Makitalo; K Karlen; C Nilsson; G Biberfeld; R Thorstensson
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

Review 3.  Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals.

Authors:  Barbara L Shacklett
Journal:  Curr HIV/AIDS Rep       Date:  2006-02       Impact factor: 5.071

4.  Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Authors:  S L Buge; L Murty; K Arora; V S Kalyanaraman; P D Markham; E S Richardson; K Aldrich; L J Patterson; C J Miller; S M Cheng; M Robert-Guroff
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.

Authors:  Liljana Stevceva; Xavier Alvarez; Andrew A Lackner; Elzbieta Tryniszewska; Brian Kelsall; Janos Nacsa; Jim Tartaglia; Warren Strober; Genoveffa Franchini
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau.

Authors:  S Andersson; O Larsen; Z Da Silva; H Linder; H Norrgren; F Dias; R Thorstensson; P Aaby; G Biberfeld
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

7.  Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.

Authors:  R P Johnson; J D Lifson; S C Czajak; K S Cole; K H Manson; R Glickman; J Yang; D C Montefiori; R Montelaro; M S Wyand; R C Desrosiers
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 8.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.

Authors:  S L Rowland-Jones; T Dong; K R Fowke; J Kimani; P Krausa; H Newell; T Blanchard; K Ariyoshi; J Oyugi; E Ngugi; J Bwayo; K S MacDonald; A J McMichael; F A Plummer
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

10.  The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12.

Authors:  I M Belyakov; J D Ahlers; B Y Brandwein; P Earl; B L Kelsall; B Moss; W Strober; J A Berzofsky
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.